Man Group
KZR

Man Group’s Kezar Life Sciences KZR Stock Holding History

Man Group’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,520
Closed -$86.2K – 2042
2023
Q2 		$86.2K Buy
+3,520
New +$91.6K ﹤0.01% 1888
2023
Q1 		– Hold
0
– – – 2002
2021
Q1 		– Sell
-1,230
Closed -$64K – 1928
2020
Q4 		$64K Buy
+1,230
New +$68.4K ﹤0.01% 1790

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Man Group's KZR Position: Q3 2023 in Review

Man Group sold out of Kezar Life Sciences (KZR) in Q3 2023, closing a stake of 3,520 shares — an estimated $86.2K sold.

Man Group first reported a position in KZR in Q4 2020 and held it in 2 quarters. The position peaked at $86.2K in Q2 2023. 82 funds tracked by Wall St. Rank hold KZR as of Q3 2023.

  • Man Group reported no remaining Kezar Life Sciences position as of Q3 2023 after selling out during the quarter.
  • Man Group sold 3,520 Kezar Life Sciences shares in Q3 2023, an estimated $86.2K.
  • Man Group first reported a position in Kezar Life Sciences in Q4 2020 and held it in 2 quarters.
  • Man Group's Kezar Life Sciences position peaked at $86.2K in Q2 2023.
  • 82 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2023.

Based on Man Group's 13F filing for Q3 2023, filed 14 Nov 2023.